- Allergy and Immunology
- Hospital Affiliation
- The Mount Sinai Hospital
Dr. Kirk Sperber is an NIH funded investigator in HIV/macrophage interactions. Dr. Sperber's current research interests are investigating the induction of T cell apoptosis by HIV-1 infected monocytes through the production of a low molecular weight peptide. His allergy research interests are the investigation of accessory cell function in gastrointestinal and respiratory epithelial cells including antigen presentation and antigen trafficking. In clinical research his interests are to investigate the anti-HIV-1 effect of hydroxyurea combined with didianosine and cloriquine as a novel therapy in third world countries. He also plays an integral role in the training of clinical fellows developing a basic science tutorial program which is well attended and highly reviewed as a valuable experience during the training period for clinical and research fellows. Additionally, he is involved in the teaching of the small groups in the 1st year medical/graduate school immunology course.
Clinical & Laboratory Immunology
American Board of Allergy & Immunology
American Board of Internal Medicine
MD, Universidad Autonoma De Guadalajara
MD, UMDNJ - Rutgers Medical School
St. Michael's Medical Center
Mount Sinai Hospital
Mount Sinai Hospital
Monocyte interactivity with HIV-1; epithelial cells; antigen trafficking
My laboratory is interested in monocyte and dendritic cell interactions with HIV-1. We have demonstrated that after HIV-1 infection, monocytes produce a low molecular weight factor that induces apoptosis in bystander T cells and B cells. We have cloned this factor now called SHIVA (Soluble HIV Apoptotic) protein using an HIV-1 infected monocyte expression library and are investigating its role AIDS dementia. We have also created a series of human dendritic cell hybridomas by fusing monocyte-derived dendritic cells with a mutagenized HAT sensitive U937. These cell lines possess many normal dendritic cell characters including CD-83 expression and IL-12 production. They can also be infected with HIV-1. We will investigate dendritic cell function after infection with different pathogens including HIV using this model system.
\r\nAnother interest of my laboratory is the role of intestinal epithelial cells in Ag processing in cow milk allergic children. We have established primary human intestinal epithelial cell lines from cow milk allergic children and demonstrated differences in patterns of trafficking of cow milk proteins compared to conventional antigens (e.g. tetanus toxoid). We have also demonstrated that intestinal epithelial cells express the novel co-stimulatory molecule B7h. We are also studying the role of CD23, the low affinity IgE receptor as a bi-directional of IgE in the intestine. We will extend these studies to better understand the role of intestinal epithelial cells in the immunopathogenesis of cow milk allergy.\r\n
So AL, Pelton-Henrion K, Small G, Becker K, Sperber K, Mayer L. Antigen uptake and trafficking in human intestinal epithelial cells. Digestive Disease Sciences 2000; 45: 1451-1461.
So AL, Small G, Becker K, Sperber K, Mayer L. Factors affecting antigen uptake by human intestinal epithelial cell lines. Digestive Disease Sciences 2000; 45: 1130-1137.
Mayer L, Sperber K, Chan L, Child J, Toy L. Oral tolerance to protein antigens. Allergy 2001; 56: 12-15.
Boelaert J, Sperber K, Piette J. Chloroquine exerts an additive in vitro anti-HIV-1effect, when combined to zidovudine and hydroxyurea. Biochemical Pharmacology 2001; 61: 1531-1535.
Rakoff-Nahoum S, Chen H, Kraus T, George I, Oei E, Sperber K. Regulation of class II expression in monocytic cells after HIV-1 infection. Journal of Immunology 2001; 167: 2331-2342.
Shiao L, Sperber K. Regulation of MHC class II expression in HIV-1 infected monocytic cells. Clinical and Diagnostic Laboratory Immunology 2002; 9: 739-746.
Sperber K, Beuria P, Singha P, Gelman E, Cortes P, Chen H, Kraus T. Induction of Apoptosis by HIV-1 infected monocytic cells. Journal of Immunology 2003; 170: 1566-1578.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Sperber is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.